Side-by-side · Research reference

SurvodutidevsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED25/54 cited

BHuman-MechanisticAUTO-DRAFTED12/40 cited

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

Survodutide

Thymalin

Primary target

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

—

Origin

—

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

Survodutide

Thymalin

Standard dose

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

5–10 mg / day IM × 5–10 daysKhavinson 2002

Frequency

Once weekly

Once daily during cycle

Route

SubcutaneousYathindra 2026

—

Evidence basis

Phase 2 RCT (obesity) · Phase 3 ongoing

Russian clinical + in vitroKhavinson 2002

Phase 2 findings

Significant weight loss and metabolic marker improvementYathindra 2026

—

MASH indication

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

—

Lower / starter dose

—

2.5 mg / day

Duration

—

5–10 day cycles, 1–2× per year

Reconstitution

—

Saline or bacteriostatic water

Timing

—

Morning preferred

Half-life

—

Hours (estimated)

03Metabolic / Fat Loss Evidence

Parameter

Survodutide

Thymalin

Primary fat target

Total body weight, visceral adipose tissue

—

Weight loss mechanism

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

—

Phase 2 efficacy

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

—

Metabolic markers

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

—

MRI-PDFF reduction

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

—

Network meta-analysis

Favorable efficacy profile vs other glucagon receptor agonists

—

Hepatic requirement

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

—

Energy expenditure

Increased energy expenditure contributes to weight lossZimmermann 2026

—

Comparative efficacy

Network meta-analysis shows competitive efficacy in GRA class

—

04Side Effects & Safety

Parameter

Survodutide

Thymalin

GI symptoms

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

—

Safety profile

Network meta-analysis: comparable safety to other GRAs

—

Serious adverse events

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

—

Injection site reactions

Expected with subcutaneous administration

—

Glucagon-related effects

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

—

Injection site reaction

—

Mild erythema at IM site

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

Survodutide

Thymalin

1. Reconstitution

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

Intramuscular — deltoid or gluteal. Rotate sites.

3. Timing

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

Morning preferred during cycle.

4. Storage

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Needle

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

23–25G, 25–38 mm IM needle.

06Stack Synergy

Survodutide

— no documented stacks

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001